GlaxoSmithKline case concluded that anti-corruption medicine has not stopped

GSK, the multinational pharmaceutical giant that lasted for more than 10 months, was involved in the investigation of suspected commercial bribery in China. GlaxoSmithKline China has obtained billions of dollars in illegal proceeds from bribing hospitals and doctors. Although the cases have come to an end, people are happy, but if China's actions to rectify the pharmaceutical industry are braked, it is likely that more "GSK" will sell high-priced drugs for the sake of self-interest and allow patients to pay.

In fact, when it comes to rectifying the high drug prices and cracking down on commercial bribery, many people in the pharmaceutical industry can tell you with their fingers, which is by no means the first act of rectification in the country. In accordance with past practice, each rectification started with great momentum, and the result was often to catch one or two typical things. The pharmaceutical companies that have avoided the limelight will soon return to their old jobs and are busy repairing tensions with doctors. It can be said that the failure to form an effective long-term supervision system and close to a gust of wind-like surprise inspection will serve as a warning, but the effect will be unsatisfactory, and it will encourage the company's chances of survival.

On the other hand, from the results of the survey, it is not an important matter. According to investigation agencies, most of the medicines sold in China by GlaxoSmithKline are under the name of overseas research drugs. Before the import of drugs, the prices of drugs for customs declaration are increased by means of transfer pricing, and some of the huge profits are pre-paid overseas. After the drug was imported, the company again requested high prices through false prices. Obviously, whether it is transfer pricing or false prices, it is not unique to GSK and it is likely to exist in multinational drug companies. If this opportunity is expanded, it is expected that the prices of foreign drug companies that are high above are expected to be high. .

It should be noted that Chinese patients will use up to 7 times the price of other countries to use GlaxoSmithKline's drugs. Who can guarantee that we do not spend more money on other multinational pharmaceutical companies?

Previously, during the survey, GlaxoSmithKline had announced the launch of global sales rectification, including the cancellation of personal sales representatives for pharmaceutical representatives, and the gradual suspension of funding for healthcare professionals to sponsor their participation in medical conferences. And other pharmaceutical giants have not clearly stated their position on the malformed sales model. This cannot but be reminiscent of people. The way of killing chickens and monkeys does not seem to have a great effect on the pharmaceutical industry. Only by continuing to increase rectification efforts can it really impact the existing pattern of illegal sales.